Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFB200603 Alone and With Tislelizumab in Advanced Solid Tumors
NCT05789069Phase 1Active, not recruiting
- Sponsor
- HiFiBiO Therapeutics
- Start
- May 2023
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of hfb200603 in renal cell carcinoma (RCC), melanoma, non-small cell lung cancer (NSCLC) and 2 more (4 arms), sponsored by HiFiBiO Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events up to 3 years and 5 more. Started May 2023; status: active, not recruiting.
02
Drugs
hfb200603
03
Conditions
renal cell carcinoma (RCC)melanomanon-small cell lung cancer (NSCLC)gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05789069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789069.